Scancell Holdings (AIM: SCLP) - action set to accelerate trial enrollment
Feb 04, 2011
| Click for PDF
Scancell Holdings (AIM: SCLP) - thesis intact, but trial enrollment slow going
Dec 16, 2010
Scancell Holdings (PLUS: SCLP) - Scancell continues to fire on all cylinders
Oct 13, 2010
| Click for PDF
Scancell Holdings (PLUS: SCLP) - bolt-on value with new licensing agreement
Aug 10, 2010
Scancell Holdings (SCLP.PLUS) - year-end results and move to AIM listing
Jul 15, 2010
Scancell Holdings (SCLP.PLUS) -Link Up With European Leader in Cutting Edge Immunotherapy Technology
Jul 02, 2010
Scancell Holdings (SCLP.PLUS) - the beat goes on as visibility increases
May 21, 2010
Scancell Holdings (SCLP.PLUS) - fully-underwritten offering to net £2.3m
Mar 09, 2010
Scancell Holdings (SCLP.PLUS) - still on track for initiation of clinical trials in Q2
Feb 05, 2010
Scancell Holdings (SCLP.PLUS) - "steady as she goes"
Dec 22, 2009
| Click for PDF
Scancell Holdings (SCLP.PLUS) - differentiated technology and a focused plan offer ingredients for success
Sep 08, 2009
| Click for PDF
Disclaimer
Objective Capital is a provider of corporate research. Our research reports provide information, analysis, and estimates and may reference our opinion on the value of highlighted companies. Objective Capital is not registered by any financial authority, and does not provide or purport to provide investment advice or recommendations of any description.
The information in this report is designed to present the opinion of Objective's analysts and what they believe to be the objective prospects of the highlighted company. Where reference is made to estimates of value or relative value of a specific company these are based on standard analysis assuming an "average" investor. There is no guarantee that these estimates are reliable or will eventuate. They should not be relied upon in forming specific investment decisions and readers should seek advice specific to their situation and investment requirements from a person authorized under the Financial Services and Markets Act 2000, before entering into any investment agreement.
Objective Capital's detailed reports are only available to ordinary business investors, market counterparties, high net-worth and sophisticated individual investors.
This report does not constitute an offer or invitation to purchase or acquire any shares in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares in any company.
The information in this report is believed to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise.
Objective Capital (including its Directors, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Objective Capital and its analysts are bared from trading in the shares of companies on which Objective Capital provides coverage.
You are reminded that the value of shares in any company may go up or down. Past performance is not necessarily a guide to future performance.
By accessing this report, you confirm that you have read and accepted this disclaimer. If you are in any doubt as to whether you are able to access this report from your jurisdiction please consult with your financial advisors before continuing.
